CytoAgents, Inc’s Post

View organization page for CytoAgents, Inc, graphic

1,386 followers

CytoAgents’ drug candidate, CTO1681, prevents and treats Cytokine Release Syndrome (CRS), which is a dangerous overreaction of the immune system. CTO1681 provides a number of advantages over other therapeutic options in treating CRS. By combining a broad mechanism of action to modulate cytokine production with a well-established safety record, it is positioned to become a new standard of care in the treatment of CRS. #cytokinereleasesyndrome #crs #cytokines #cartcelltherapy Teresa Whalen, RPh

  • No alternative text description for this image

To view or add a comment, sign in

Explore topics